Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
46.9M
-
Shares change
-
+6.82M
-
Total reported value, excl. options
-
$627M
-
Value change
-
+$87.7M
-
Put/Call ratio
-
0.76
-
Number of buys
-
49
-
Number of sells
-
-45
-
Price
-
$13.35
Significant Holders of Coherus Oncology, Inc. - Common Stock (CHRS) as of Q3 2017
126 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock as of Q3 2017.
Coherus Oncology, Inc. - Common Stock (CHRS) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.9M shares
of 115M outstanding shares and own 40.66% of the company stock.
Largest 10 shareholders include FMR LLC (7.71M shares), Temasek Holdings (Private) Ltd (6.56M shares), WELLINGTON MANAGEMENT GROUP LLP (6.28M shares), BlackRock Inc. (3.28M shares), Kohlberg Kravis Roberts & Co. L.P. (3.06M shares), VANGUARD GROUP INC (2.47M shares), STATE STREET CORP (1.88M shares), JPMORGAN CHASE & CO (1.75M shares), UBS ASSET MANAGEMENT AMERICAS INC (1.32M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.21M shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.